Rodman & Renshaw, LLC, a leading investment bank, initiated research coverage of Provectus Pharmaceuticals, Inc. (PVCT) by granting the company a Market Perform Rating.
Provectus Pharmaceuticals, a leading Pharmaceutical company, specializes in developing oncology and dermatology therapies that are safer, more effective, and less invasive than current therapies. Currently, Provectus is conducting Phase 2 clinical trials of two of their proprietary drugs, PV-10 and PH-10. PV-10 is used as to treat melanoma and breast cancer, and PH-10 as a topical treatment for moderate to severe psoriasis. The Company has already received orphan drug designation from the FDA for metastatic melanoma.
Rodman & Renshaw is a full service investment bank, dedicating in providing investment banking services to companies with recurring capital needs. Rodman & Renshaw is focused on research, sales, and trading services to institutional investor clients that focus on such companies. Through Renshaw’s AcumenBioFin division, Rodman provides advantageous investment banking services for biotechnology companies, as well as PIPE (private investment in public equity) transactions.
Let us hear your thoughts: Provectus Pharmaceuticals, Inc. Message Board